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health care claims database and the claims and medical charts for a subset of this 
population were reviewed to extract information pertaining to disease-modifying 
therapy, corticosteroid therapy, MS-related procedures, and diagnosis and relapse 
dates. The agreement between the data sources for each type of information was 
identiﬁed. RESULTS: From a total population of 11,326 MS patients in the claims 
database, 300 had their medical records reviewed. Among patients with claims for 
glatiramer acetate (n = 68), 95.6% also had it indicated in their charts. Claims agreed 
with charts for 91.8% of patients with a claim for intramuscular interferon β-1a (n = 
85), 81.8% of patients with a claim for subcutaneous interferon β-1a (n = 55), and 
87.5% of patients with a claim for interferon β-1b (n = 48). Methylprednisolone was 
the most commonly indicated corticosteroid in both data sources, and among patients 
with evidence of a methylprednisolone ﬁll in the claims (n = 114), 66.7% also had a 
prescription indicated in their chart. Most patients with claims-based evidence of 
MS-related procedures also had them indicated in their charts: 71.0% with MRI, 
81.0% with lumbar puncture, and 66.7% with evoked potential testing. For both 
diagnosis and relapse dates, at least half of the patients had perfect agreement. CON-
CLUSIONS: Claims and medical charts provide complementary information with a 
degree of overlap. Claims appear to approximate chart data with regard to certain 
MS-related variables, such as dates and disease-modifying therapy, but the data 
sources also provide unique information which might be differentially suited to 
addressing diverse research questions.
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OBJECTIVES: Since its development in the 80’s, variations of the Alzheimer’s Disease 
Assessment Scale-Cognitive subscale (ADAS-Cog), a Clinician-Reported Outcome 
(ClinRO) measure, have been used to monitor disease progression and treatment 
efﬁcacy in Alzheimer’s disease. The objective of this study was to identify all versions 
used as a basis for translation in Mapi Institute projects and to take stock of existing 
translations. METHODS: The review was based on all ADAS-Cog translation projects 
performed by Mapi Institute. RESULTS: Sixteen projects were identiﬁed representing 
a total of 70 languages and 219 translations. Translations were based on 11 source 
versions which differed in terms of content (number of items, order of items and 
instructions), and format. The number of items ranged from 11 to 15. Four studies 
used 13 items, but only in two cases the same items were used but in a different order. 
Four studies used 12 items: only two studies used the same items (with a different list 
of words for the Word Recognition Task), but again in a different order. Format and 
instructions differed in all cases. In most projects the source version provided by the 
sponsor was a single document mixing instructions with the rater and response forms. 
Only in 3 cases the original consisted in a separate instruction manual and response 
forms. With regard to available translations, more than one translation was identiﬁed 
in 56 of the 70 available languages and in one language as many as 7 translations. 
CONCLUSIONS: The abundance of different versions of the same questionnaire both 
in its original US English form as in translation makes comparisons between studies 
or pooling of data difﬁcult for both researchers and users. In the light of FDA’s recent 
PRO guidance it would be beneﬁcial to demand the same scientiﬁc rigor when using 
ClinROs in international studies.
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OBJECTIVES: Explore the effect of adjusting for multiple comparisons in analyzing 
outcome variables between more than two strata. METHODS: Health-related quality 
of life (HRQoL) via SF-12 Health Survey was measured at baseline for 191 patients 
in a U.S. multiple sclerosis observational study. HRQoL was summarized in two 
continuous variables: Physical Component Score (PCS-12) and Mental Component 
Score (MCS-12). Patient work status was expressed by one categorical variable with 
four values: Working Full-time (W), Working Part-time (WP), Not Working due to 
MS (NW-MS), Not Working due to other reasons (NW). Generalized linear models 
were used to measure the overall association HRQoL and work status. Pairwise 
comparisons were conducted between the HRQoL means with respect to each of the 
four categories of work status. The Bonferroni method was used to control the fami-
lywise error rate under multiple comparisons test. RESULTS: Overall association 
between Work Status and HRQoL was statistically signiﬁcant (p-values: <.001 for all 
measures), suggesting that HRQoL differs by work status. Pairwise comparisons 
showed that only the NW-MS group was statistically signiﬁcantly different from all 
other groups (all p-values <.001) in PCS-12 and different from W and WP groups in 
MCS-12 (p-value: W = 0.03, WP = < .001), while all other comparisons were not 
signiﬁcantly different from each other. If the Bonferroni adjustment is not applied, the 
pairwise comparisons lead to more differences being signiﬁcant (p-value: W vs WP = 
0.04 in PCS-12 and MCS-12). CONCLUSIONS: Even though the overall association 
between two variables may be statistically signiﬁcant, if the categorical variable has 
more than two categories, then applying multiple comparisons adjustments to all 
pairwise comparisons more appropriately tests the statistical signiﬁcance of the differ-
ences between these individual categories. Neglecting to account for the fact that 
multiple comparisons are being made may lead to erroneous conclusions about dif-
ferences in outcomes.
SENSORY SYSTEMS DISORDERS – Clinical Outcomes Studies
PSS1
BEVACIZUMAB FOR NEO-VASCULAR AGE RELATED MACULAR 
DEGENERATION—EVIDENCE SUMMARY
George PP1, Molina JAD1, Heng BH1, Tan NWH2, Lim TH2
1National Healthcare Group (NHG), Singapore, Singapore, 2NHG Eye Institute, Tan Tock 
Seng Hospital, Singapore, Singapore
OBJECTIVES: To evaluate evidence on effectiveness of intravitreal Avastin for neo-
vascular age related macular degeneration (AMD). METHODS: We searched the 
Medline database for articles on bevacizumab for neo-vascular AMD, published 
between January 1, 2005 and September 1, 2009. The search criteria were English 
language manuscripts, human studies and search terms “bevacizumab”, “Avastin”, 
“age-related macular degeneration”, “ARMD”, “AMD”,”intra-vitreal” as a major 
heading. Boolean operators were used to combine the search terms. Studies in which 
primary outcome measures were visual acuity (VA) and central retinal thickness (CRT) 
were included for review. Two reviewers independently selected studies, assessed 
methodological quality using Scottish Intercollegiate Grading Network (SIGN) system. 
RESULTS: Overall, there were 520 citations, of which only 216 were relevant after 
title and abstract screening. Sixty-seven manuscripts were ﬁnally included for review, 
of which three were systematic reviews, three were randomized Controlled Trials 
(RCT), 49 were pre-post/ non-randomized studies and 13 were studies on safety and 
adverse effect. Three RCTs show bevacizumab to be more effective than PDT (with 
or without triamcinolone). However, these RCTs had several methodological issues; 
evidence from these RCT’s was of moderate quality. Several pre-post and non-ran-
domized studies have also suggested the effectiveness of bevacizumab, but these studies 
had several design limitations and hence the quality of evidence was deemed poor. 
Pooled outcome estimates, showed bevacizumab therapy,on average, improved VA by 
nine EDTRS letters and reduced CRT by 90 μm. Incidence of adverse events was low, 
similar to ranibizumab. Currently moderate (grade B) to poor quality of evidence is 
available in support of bevacizumab for neo-vascular AMD. CONCLUSIONS: Based 
on current evidence (grade B) off-label Intravitreal bevacizumab seems to be safe and 
effective for the treatment of neo-vascular AMD in the short term, especially for 
underserved and ﬁnancially challenged communities.
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OBJECTIVES: Conduct a return on investment (ROI) analysis of 8 ablative fractional 
lasers used for cosmetic facial plastic surgery from the perspective of a facial plastic 
surgeon. METHODS: We identiﬁed 8 of the largest (based on sales volume) ablative 
fractional lasers for this analysis. ROI is (ΣTotal Revenue–ΣTotal Cost)/(ΣTotal Cost) 
and is deﬁned as the additional dollar returned from each dollar invested. Revenue 
was estimated as price per procedure multiplied by total number of procedures in a 
year. Total cost is a composite of purchase price and operating costs. In the base case 
analysis two purchase options were assumed 1) a 5 year lease with a $0 down payment 
and 2) a 3 year lease with a $0 down payment. In addition to monthly lease payments, 
included in the total cost estimate were service contracts, labor costs, and disposables. 
Sensitivity analyses were preformed to account for variability in cost and revenue 
assumptions. RESULTS: Revenue for each laser was estimated to be $51,072/year. 
Under a 5 year lease, the assumed total cost of each laser ranged from $115,827–
$240,597. This is compared to the total cost under a 3 year lease of each laser which 
ranged from $74,364–$124,878. Average ROI under the 5 year lease term was .54 
and ROI varied between −.03 (most expensive laser) and 1 (least expensive laser). The 
average 3 year ROI was .08, and ROI varied between -.35 (most expensive laser) and 
.38 (least expensive laser). CONCLUSIONS: Based on the assumptions of our analysis 
the laser with highest ROI was the least expensive laser. While ROI is an important 
ﬁnancial it should not be the sole means by which to determine a purchase. Physicians 
must also consider the clinical effectiveness of each laser and their own clinical judg-
ment when making such decisions.
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OBJECTIVES: Evaluate the annual cost of Dry Eye Diseases (DED) care in the United 
States from both a societal and a payer’s perspective METHODS: A decision-tree 
model was developed to estimate the annual cost for managing a cohort of DED 
patients with differing severity of symptoms and treatments utilizing data collected 
from survey and the literature. The direct costs included over the counter (OTC) 
medications, cyclosporine, punctal plugs, physician visits, and nutrition complements. 
The indirect costs were computed based on the self-reported productivity loss includ-
ing absenteeism and presenteeism. Multiple-one way sensitivity analysis was employed 
to evaluate the impact of changes in parameters within their 95% conﬁdence intervals 
on the cost estimate. RESULTS: In the base-case analysis, the total mean annual direct 
